Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
React to this article
Latest news
Date Title
<1m ago GOODYEAR TIRE & RUBBER : to Present at 2015 Deutsche Bank Global Auto Industry Conference
<1m ago NORTHERN : to Webcast Fourth Quarter 2014 Earnings Conference Call
1m ago EMPIRIC STUDENT PROPERTY : Non-Executive Buys Shares (DIRECTOR DEALINGS)
2m ago GUARANTY FEDERAL BANCSHARES : Other Events, Financial Statements and Exhibits (form 8-K)
2m ago SONY : Decision to reel back movies draws scorn
2m ago FLAMEL TECHNOLOGIES : announces Second Clinical Trial with Micropump Sodium Oxybate
2m ago ASE ALLIANCE TO SAVE ENERGY : Study: Aluminum Cans Still Sustainable Beverage Package of Choice
2m ago SAP SE : December 19, 2014SAP Recognized as a Market Leader by Gartner in 2014 Operational Database Management Systems Magic Quadrant ›
2m ago LOCKHEED MARTIN : Built MUOS-3 Secure Communications Satellite Encapsulated in Launch Vehicle Fairing
2m ago UNIPETROL : Czech antimonopoly office (ÚOHS) approved acquisition of 32.445 percent stake in Ceská rafinérská from Eni
Latest news
Advertisement
Hot News 
DIXONS CARPHONE : *exane bnp raises dixons carphone price target to 510 (450) pence - 'outperform'
BERKELEY MINERAL RESOURCES : Obsidian IR
ATLANTIS RESOURCES : Makes First MeyGen Facility Drawdown
FINISH LINE : Reports Third Quarter Fiscal Year 2015 Results
MARTINCO : More unwelcome surprises regarding deposit protection
Most Read News
1d ago Wall St. has best second-day gain since 2011 on Fed optimism
1d agoDJKEPPEL LAND : Correction to Keppel Land to Buy 75% Stake in Array Article (on Friday)
1d ago WELLS FARGO : exec Petrilla is new head of state's California-China trade office
1d ago Unilever drops mayonnaise suit against Just Mayo maker
1d ago Brazil's Rousseff vows clean-up of scandal-tainted Petrobras
Most recommended articles
3m agoDJBank of Mexico Unanimous in Holding Interest Rates
3m agoDJJUNO THER : peutics Shares Surge in Market Debut
5m agoDJTwo Dead in Explosion at Oklahoma Oil Rig
10m agoDJBank of Mexico Unanimous in Holding Interest Rates
17m agoDJConsumer Confidence in the Eurozone Likely to Edge Up
Dynamic quotes  
ON
| OFF